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Kounis syndrome is charac­
terised by a group of symp­
toms that manifest as unsta­
ble vasospastic or non­vaso­
spastic angina secondary to a 
hypersensitivity reaction.[1] It was first described by 
Kounis and Zavras in 1991[2] as the concurrence 
of an allergic response with an anaphylactoid 
or anaphylactic reaction and coronary artery 
spasm or even myocardial infarction. Since 
then, this condition has evolved to include 
a number of mast cell activation disorders 
associated with acute coronary syndrome. 
There are many triggering factors, including 
reactions to multiple medications (non­steroidal 
anti­inflammatory drugs, antibiotics and anti­
neoplastic agents), exposure to radiological 
contrast media, poison ivy, bee stings, shellfish 
and coronary stents. In addition to coronary 
arterial involvement, Kounis syndrome com­
prises other arterial systems with similar 
physiologies, such as mesenteric and cerebral 
circulation resulting in ischaemia/infarction of 
the vital organs.[3,4] The incidence of Kounis 
syndrome is difficult to establish owing to the 
number of potential instigating factors and 
its relatively infrequent documentation in 
the literature. It remains unclear whether the 
reported lower rates of the condition are the 
direct result of underdiagnosis. 
We report the case of an HIV­negative 
39­year­old man with no coronary risk factors 
or family history of premature coronary artery 
disease, who developed Kounis syndrome 
after the administration of fluoroquinolone for 
dysuria. However, to the best of our knowledge, 
no data on the incidence and prevalence of 
Kounis syndrome in South Africa (SA) have 
ever been reported in the literature. The recent 
understanding of Kounis syndrome has led to 
the classification of this condition into three 
syndrome variants.[2]
Case report
Our patient was a 39­year­old man with 
excellent baseline health. His history is signi­
ficant because of exercise­induced asthma in 
childhood and an allergic reaction to cefixime 
in 2008 that responded well to antistamine and 
corticosteroids. In 2009 he was administered 
ciprofloxacin, with no untoward reaction. He 
was well until February 2015, when he developed 
dysuria and was administered ciprofloxacin. The 
patient developed a red pruritic rash 15 minutes 
after ingestion of the drug, which was followed 
by swelling of his hands, feet and scrotum. 
Four hours later, he developed retrosternal 
chest pain, radiating to both shoulders, rated 
8/10, which persisted for about 10 minutes, 
with diaphoresis and nausea. The following 
morning he presented at the emergency centre, 
and developed a second episode of typical chest 
pain. The ECG (Fig. 1) showed ST segment 
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Fig. 1. ECG demonstrating inferior and posterolateral ST elevation.
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elevation in the inferior leads, and a diagnosis of 
acute coronary syndrome with inferior, postero­
lateral myocardial infarction was made. He 
was thrombolysed with tenecteplase, with no 
resolution of ST segment elevation 1 hour post 
lysis. The patient was referred to our division 
for rescue percutaneous coronary intervention 
(PCI) after stat doses of aspirin, clopidogrel and 
atenolol. On arrival, on re­taking the history, 
allergic myocardial infarction was considered 
a likely diagnosis and blood was sent for 
determination of troponin, tryptase, and IgE 
(Table 1). 
The clinical examination was unremarkable: the 
patient was normotensive, with a blood pressure 
of 120/70 mmHg, tachycardia of 108 beats/
minute, and tachypnoea of 22 breaths/minute. 
Cardiovascular examination revealed a loud S1 
and no murmurs. Prednisone 1 mg/kg/day, 
diphenhydramine 50 mg, ranitidine 150 mg 
and amlodipine 10 mg were administered 
orally, with resolution of pain and ECG 
changes. Administration of aspirin, clopidogrel 
and a beta­blocker was discontinued. Cardiac 
catheterisation and a coronary angiogram 
were performed within 24 hours and showed 
unobstructed coronary arteries (Figs 2 and 3). 
On receipt of the blood results, allergologists 
were consulted. The patient was discharged 
3 days later with no resurgence of symptoms; 
also not at 3 months’ follow­up.
Discussion
Kounis syndrome was described in 1991 as 
the concurrence of acute coronary events with 
an allergic or a hypersensitivity response and 
an anaphylactic or anaphylactoid reaction.[2] 
Several possible causes of Kounis syndrome 
have been reported.[1,5,6] The condition has 
three variants,[1] i.e. type 1 – coronary spasm; 
type 2 – coronary thrombosis; and type 3 – 
drug­eluting stent thrombosis. It is important 
to distinguish the type, as it has management 
implications. The syndrome is caused by 
inflammatory mediators released mainly 
from activated mast cells and via bidirectional 
stimuli macrophages and T­lymphocytes.[1] 
As activated mast cells abound at the areas of 
plaque erosion or rupture in patients suffering 
from acute myocardial infarction, a common 
pathway between allergic and non­allergic 
coronary events seems to exist.[1,7]
• Type 1 variant includes patients with 
normal coronary arteries without 
predisposing factors for coronary artery 
disease, in whom the acute release of 
inflammatory mediators can induce 
either coronary artery spasm without an 
increase in cardiac enzymes and troponins 
or coronary artery spasm progressing to 
acute myocardial infarction with raised 
cardiac enzymes and troponins.[1]
• Type 2 variant includes patients with 
culprit, but quiescent, pre­existing athero­
matous lesions, in whom the acute release 
of inflammatory mediators can induce 
either coronary artery spasm with normal 
cardiac enzymes and troponins or plaque 
erosion or rupture manifesting as acute 
myocardial infarction.[1]
• Type 3 variant includes patients with coronary 
thrombosis (including stent thrombosis), 
in whom aspirated thrombus specimens 
stained with haematoxylin­eosin and Giemsa 
demonstrate the presence of eosinophils and 
mast cells, respectively.[1]
Histamine released by degranulation of 
mast cells can also be measured within 
5 ­ 10 minutes, but remains elevated for 
only 30 ­ 60 minutes and therefore has 
very limited value. To date, serum tryptase 
has been identified as a reliable marker of 
an anaphylactic reaction. Review of the 
literature has suggested that serum tryptase 
may be considered as a new marker of 
the instability of atheromatous plaque with 
regard to the existence of mastocytes in 
heart tissue. Regardless of documented 
laboratory evidence of anaphylaxis, a 
diagnosis can still be made based on the 
clinical presentation and treatment carried 
out accordingly.[5]
Treatment depends on the syndrome 
variant:
• Type 1 variant: treatment of the allergic 
event alone may abolish type 1 variant. 
Administer corticosteroids, antihistamines, 
vaso dilators (e.g. nitrates), and calcium 
channel blockers.[3,8]
• Type 2 variant: apply the acute coro nary 
event protocol and administer cortico­
steroids, antihistamines, vasodila tors (e.g. 
nitrates), and calcium channel blockers 
when appropriate. 
• Type 3 variant: the use of mast cell 
stabilisers in association with steroids 
and antihistamines is recommended. 
Harvesting of the intrastent thrombus 
together with histological examination of 
Table 1. Results of investigations
Investigation Result
Full blood count Haemoglobin 13.3 g/dL; white cell count 8.34 × 109/L; 
platelet count 276 × 109/L; eosinophils 0.017 × 109/L (0.3%)
Urea and electrolytes Na 143 mmol/L; K 4.6 mmol/L; urea 3.6 mmol/L; 
creatinine 77 µmol/L
Total IgE 43 kU/L
Thyroid­stimulating hormone 0.36 mIU/L
Antinuclear antibodies 0.1 ratio – negative
Mast cell tryptase 2.5 µg/L
HIV Negative
Lipid profile Total cholesterol 2.8 mmol/L; triglyceride 0.9 mmol/L; 
high­density lipo protein 1 mmol/L; 
low­density lipoprotein 1.3 mmol/L
Troponin T 1 001 ng/L
Diverse cast ciprofloxacin Positive
Fig. 2. Unobstructed left coronary artery.
Fig. 3. Unobstructed right coronary artery.
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aspirated material and staining for eosinophils and mast cells 
should be undertaken. 
When allergic symptoms are present after stent implantation, 
desensitisation measures should be applied; if these fail, the stent 
should be extracted.
Conclusion
There is a paucity of data on the incidence and prevalence of 
Kounis syndrome in SA; nonetheless, it is important to be aware 
of the entity. There are no treatment guidelines for patients with 
this syndrome, and most of the treatment information has been 
gathered from individual case reports or case series. A diagnosis of 
Kounis syndrome should be considered in young, healthy patients 
with no atherosclerotic risk factors when they develop an acute 
coronary syndrome (especially inferior myocardial infarction) after 
administration of a potentially allergic agent. These patients need 
treatment with steroids, antihistamines, fluid resuscitation, possibly 
adrenaline, oxygen, and antithrombotic agents before transfer to 
a cardiac catheterisation laboratory. An allergy work­up should 
include the assessment of allergies to food, insect bites and other 
environmental agents. Skin tests and food challenges may be useful 
in identifying the culprit agent.
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